Clinical

  • Clinical Solutions
  • AI solutions portfolio

Explore Aiforia’s comprehensive portfolio of high-performance AI solutions, engineered for both clinical and preclinical applications. Aiforia’s solutions aim to enhance the speed, accuracy, and consistency of analyzing large and complex medical images, especially in pathology.

Learn more

Research

  • Research solutions
  • Aiforia® Create
  • AI solutions portfolio

Aiforia’s research solutions offer fully automated study-centric workflows and pathology image analysis applications that cater to all research areas. Empowered by robust AI capabilities, pathologists and scientists can make discoveries while saving time by automating repetitive tasks – also within the framework of GLP. Aiforia’s solutions can be integrated with any existing laboratory infrastructure to enjoy the full benefits of a digitized workflow.

Learn more

Aiforia® Create is the most versatile tool for developing deep learning AI models for image analysis in digital pathology. Its cloud-based, collaborative working environment allows multiple users to work together in real time, anywhere in the world. Praised for its intuitive user interface, it allows users a fast start, even without any prior AI experience.Learn more >

Learn more

Explore Aiforia’s comprehensive portfolio of high-performance AI solutions, engineered for both clinical and preclinical applications. Aiforia’s solutions aim to enhance the speed, accuracy, and consistency of analyzing large and complex medical images, especially in pathology.

Learn more

AI development tool

  • Aiforia® Create

Aiforia® Create is the most versatile tool for developing deep learning AI models for image analysis in digital pathology. Its cloud-based, collaborative working environment allows multiple users to work together in real time, anywhere in the world. Praised for its intuitive user interface, it allows users a fast start, even without any prior AI experience.

Learn more

Resources

  • Publications
  • Resource Library
  • Press releases

Explore some of our latest publications showcasing the discoveries enabled by the Aiforia® Platform.

Learn more

Aiforia's insights and resources for AI in pathology. View some of our content pieces from the world of AI.

Learn more

Stay updated with Aiforia’s recent announcements. Explore our latest news, updates and announcements.

Learn more

Company

  • About us
  • Investors
  • Partners
  • Media
  • Events
  • Careers
  • Quality and security

Find out more about shareholder matters, investment discussions, and financial-related information.

Learn more

Aiforia's mission is to transform pathology image analysis with AI, enabling better care for each patient. To succeed, we need our trusted partners. Explore Aiforia’s partner network.

Learn more

Experience our AI solutions firsthand. Explore the list of conferences where you can connect with Aiforia’s team live and book a time to discover the future of AI-powered image analysis.

Learn more

Our mission is to transform pathology image analysis with AI, enabling better care for each patient. Find out more about job openings, thesis opportunities, or submitting applications.

Learn more

Aiforia Technologies holds information security to the highest standard. We hold several, globally relevant quality and security certifications, so you can be sure your sensitive information is safe.

Learn more

Research

Research solutions

Aiforia® Create

AI solutions portfolio

AI development tool

Aiforia® Create

Resources

Publications

Resource Library

Press releases

CRL case study: AI-assisted screening of bone marrow cellularity changes

Veterinary pathologist, Mark Smith, from Charles River Laboratories describes using AI models to screen for bone marrow cellularity changes.
Written by Aiforia

Bone marrow cellularity is the volume ratio of hematopoiesis (the body’s manufacturing of blood cells) and fat, and it decreases with age. Many compounds can alter the cellularity of bone marrow, making it a vital tissue for pathologists to analyze in pharmacologic safety studies. Quantitative data is vital for statistical evaluation in risk and toxicity assessments.


AI provides objectivity

However, the important analytical information of these studies is often represented by images, which lack unambiguous and objective criteria for analysis as interpretation of these images is largely affected by the experience of the researcher. Specialists in toxicology are often also not trained in translating results into mathematical statistical models, while specialists in mathematical statistics and modeling lack knowledge of the specificity of risk assessment and methods in toxicology.

AI models provide a more objective quantification of bone marrow cellularity and increase the reliability of image analysis by evaluating a larger area and providing accurate cell counts compared to a pathologist’s subjective severity score. Objective data is also statistically analyzable to evaluate against other study data, and the nature of AI model generation for image analysis allows for continuous improvement of the AI model with new training data.

A research team at Charles River Laboratories (CRL) developed an AI model with Aiforia® Create to evaluate whole slide images of macaque sternebrae to identify and enumerate bone marrow hematopoietic cells. The AI model was trained to differentiate the hematopoietic cells from the other sternebrae tissues and serves as an objective measure of bone marrow cellularity in tissue sections. Learn more from Mark Smith, PhD VMD, Veterinary Pathologist at CRL, in his interview below and from this on-demand webinar.

Review the full publication: Screening for bone marrow cellularity changes in cynomolgus macaques in toxicology safety studies using artificial intelligence models

 

Tell us a bit about the project or research work you used Aiforia for

Mark Smith: "Bone marrow is a standard tissue for analysis in pharmacologic safety studies.

Xenobiotic compounds can alter the cellularity of bone marrow. Anatomic pathologists evaluate bone marrow in hematoxylin and eosin-stained bone sections, diagnose increases or decreases in cellularity, and assign a subjective severity score. We felt an Artificial Intelligence model might be able to determine cellularity in a more objective manner and serve as a screening tool to alert study pathologists to changes in bone marrow cellularity.

What is unique about the project?

"There is no current AI model that quantifies the number of cells in the bone marrow from a histologic section."

laptop-1

 

Why did you decide to use Aiforia?

"The Aiforia® Platform is cloud-based and accessible without the need to install software and was fairly easy to learn."

How did you find getting started with Aiforia?

"After an hour or so of instruction, training the model was straightforward, as was subsequent troubleshooting to improve it. In short, it was a smooth start."

What is the biggest benefit of Aiforia to your work?

"The model will provide useful data on bone marrow cellularity, which can be used to screen slides and draw attention to potential lesions. A similar effort by a pathologist would be very time-consuming and not practical."

References

Ignatova, A. & Zemlyanova, M. (2020, November 10). Proceedings of the 8th scientific conference on information technologies for intelligent decision making support (ITIDS 2020). Atlantis Press. https://doi.org/10.2991/aisr.k.201029.068 

Smith, M. et al. (2021, January 5). Screening for bone marrow cellularity changes in cynomolgus macaques in toxicology safety studies using artificial intelligence models. Sage Journals. 49(4). https://doi.org/10.1177/0192623320981560 

Weng, C. et al. (2015, February 24). Bone marrow pathology predicts mortality in chronic hemodialysis patients. BioMed Search International. https://doi.org/10.1155/2015/160382 

WANT TO FIND OUT ABOUT AIFORIA’S AI SOLUTIONS?

Send us a message!